Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias.
Bioengineered
Li S, Wang Z, Guo X, Chen P, Tang Y.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2022
Cancer Research
No items found.
Key Finding
In vivo studies demonstrated that Hm3A4-Rap had potent anti-leukemia activity, with dosed mice showing a significant increase in survival time compared to control mice (P < 0.01). In summary, the study's immunotoxin had excellent biological activity suggesting its potential therapeutic value for treating AML patients.
Countstar Connection
The study obtained cell-count measurements from the study's cell samples with Countstar (model not specified) during quality assessment in the 2022 Bioengineered study.
